U.K. cancer fund strikes discount deal with Roche to keep Kadcyla covered

Last month, the U.K.'s special Cancer Drugs Fund gave the boot to a slate of therapies, including Roche's ($RHHBY) treatment Kadcyla--a decision the Swiss drugmaker's CEO called "stupid" and "completely arbitrary." Now, though, the fund and Roche have reached a discount deal--meaning Kadcyla is set to stay. Story | More